Who
Jennifer L. Good
Director
Company insider
Files Form 4 as: Director, Rhythm Pharmaceuticals; President & CEO, Trevi Therapeutics; Director, Juniper Pharmaceuticals; President & CEO, Penwest Pharmaceuticals Co.
In numbers
- Trades disclosed
- 107
- Buys
- 2
- Sells
- 11
- Bought
- $129K
- Sold
- $4.6M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 9 Feb 2006
- Last trade
- 24 Jun 2026
- Last filed
- 25 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,691 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,691 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,324 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,324 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —4,712 | filing |
| 23 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,712 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,712 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —4,712 | filing |
| 19 Feb 2026filed 20 Feb 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —675,000 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —675,000 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,037 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,712 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,000 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —4,000 | filing |
| 31 May 2025filed 3 Jun 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —102,000 at $0.00 | filing |
| 21 Mar 2025filed 25 Mar 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,263 at $0.00 | filing |
| 21 Mar 2025filed 25 Mar 2025 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $7,5265,263 at $1.43 | filing |
| 21 Mar 2025filed 25 Mar 2025 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $35K5,263 at $6.58 | filing |
| 10 Mar 2025filed 12 Mar 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,400 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —811,000 at $0.00 | filing |
News
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic ObesityRYTM · manilatimes.net · 14 Oct 2026Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual MeetingTRVI · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Jennifer L. Good; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.